跳至主要内容
临床试验/NCT00361790
NCT00361790已完成1 期

Effects on Aripiprazole on the Steady-State Pharmacokinetics of Escitalopram in Healthy Subjects

Otsuka Pharmaceutical Development & Commercialization, Inc.1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2006年8月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
25
试验地点
1
主要终点
Multiple dose PK parameters for Lexapro when administered alone and coadministered with aripiprazole will be derived. Cmin for aripiprazole,dehydro-aripiprazole will be measured

研究概览

简要总结

The purpose of this clinical research study is to learn whether aripiprazole has effect on the steady-state pharmacokinetics of escitalopram in healthy subjects. The safety and tolerability of aripiprazole and escitalopram co-administration will also be studied.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
盲法
None

入排标准

年龄范围
18 Years 至 45 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Healthy male and female subjects, ages 18 to
  • (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the study in such a manner that the risk of pregnancy in minimized.
  • Body Mass Index (BMI) of 18 to 33 kg/m2 inclusive.

排除标准

  • Subjects with a decrease in SBP of >=20 mm Hg and increase in HR of >=20 bpm after 2 minutes standing vs. 2 minutes supine at screening or with frank orthostatic hypotension at screening.
  • Supine BP of 90/50 mm Hg or lower at screening.

结局指标

主要结局

Multiple dose PK parameters for Lexapro when administered alone and coadministered with aripiprazole will be derived. Cmin for aripiprazole,dehydro-aripiprazole will be measured

次要结局

  • Safety will be based on review of AEs, VS, ECGs, physical exam, clinical labs

研究者

研究点 (1)

Loading locations...

相似试验